Caso, Raul
Connolly, James G.
Zhou, Jian
Tan, Kay See
Choi, James J. http://orcid.org/0000-0002-6988-8648
Jones, Gregory D. http://orcid.org/0000-0003-4749-6528
Mastrogiacomo, Brooke
Sanchez-Vega, Francisco
Nguyen, Bastien
Rocco, Gaetano
Molena, Daniela http://orcid.org/0000-0003-1655-4473
Sihag, Smita
Adusumilli, Prasad S.
Bott, Matthew J.
Jones, David R. http://orcid.org/0000-0002-3318-0146
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA217169, R01CA240472, P30 CA008748, T32CA009501, R01CA236615)
Hamilton Family Foundation, Marie-Josée and Henry R. Kravis Center for Molecular Oncology
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Defense (LC160212)
Article History
Received: 25 January 2021
Accepted: 29 June 2021
First Online: 21 July 2021
Competing interests
: G.R. has financial relationships with Scanlan. D.M. is a consultant for Johnson & Johnson, Urogen, Intuitive, and Boston Scientific. P.S.A. has received research funding from ATARA Biotherapeutics and Acea Biosciences, has served on the Scientific Advisory Board or as consultant to ATARA Biotherapeutics, Bayer, Carisma Therapeutics, Imugene, and Takeda Therapeutics, and has patents, royalties, and intellectual property on mesothelin-targeted CARs and other T-cell therapies, method for detection of cancer cells using virus, and pending patent applications on T-cell therapies. M.J.B. serves as a consultant for AstraZeneca. D.R.J. serves as a consultant for AstraZeneca and is on a Clinical Trial Steering Committee for Merck. All other authors have no potential conflicts to disclose.